When we combine the three studies (from Poland, UK, and the Netherlands), truncating mutations of XRCC2 were detected in 38 of 29,252 (0.13%) breast cancer cases versus 16 of 11,522 (0.14%) controls and were not associated with breast cancer risk (meta-analysis OR = 0.88, 95% CI 0.50–1.57, Mantel–Haenszel method). This evidence concerns the gene XRCC2 and breast carcinoma.